RLMD
Relmada TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that RLMD now has a reset pipeline with NDV-01 as the lead asset, sepranolone as a second program, and enough cash to reach targeted mid-2026 development milestones; successful IND/trial-start execution could move the stock closer to its sparse published target backdrop [#10-K-2026-03-19].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +21.2.
What can break
Additional financing or partnering may be needed beyond the stated 12-month funding horizon.
Momentum
24
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $10.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.67
Why
Momentum24 · Δ7d +4.6
Value41 · Δ7d -0.1
Sentiment83 · Δ7d +21.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
24
26% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
-17.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
83
34% active weight
Current posture
7d trendImproving
Δ7d
+21.2
Δ21d
+28.3
Why this grade
Composite grade C. Momentum 23.8 / Value 41.1 / Sentiment 83.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$549.62M
Beta
0.78
Shares Out
104.89M
P/E (TTM) · Derived
-3.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.69
Rev YoY
-
EPS YoY
-61.9%
Gross Margin
-
Op Margin
-
Net Debt
-$93.01M
Current Ratio
18.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology